PURPOSE: [(18)F]FEDAA1106 is a recently developed positron emission tomography (PET) radioligand for in vivo quantification of the 18 kDa translocator protein [TSPO or, as earlier called, the peripheral benzodiazepine receptor (PBR)]. TSPO imaging is expected to be useful for the clinical evaluation of neuroinflammatory diseases. The aim of this study was to provide dosimetry estimates for [(18)F]FEDAA1106 based on human whole-body PET measurements. METHODS: PET scans were performed for a total of 6.6 h after the injection of 183.8 ± 9.1 MBq of [(18)F]FEDAA1106 in six healthy subjects. Regions of interest were drawn on coronal images. Estimates of the absorbed doses of radiation were calculated using the OLINDA software. RESULTS: Peak uptake was largest in lungs, followed by liver, small intestine, kidney, spleen and other organs. Peak values of the percent injected dose (%ID) at a time after radioligand injection were calculated for the lungs (27.1%ID at 0.2 h), liver (21.1%ID at 0.6 h), small intestine (10.4%ID at 6.3 h), kidney (4.9%ID at 1.8 h) and spleen (4.6%ID at 0.6 h). The largest absorbed dose was found in the spleen (0.12 mSv/MBq), followed by kidneys (0.094 mSv/MBq). The calculated mean effective dose was 0.036 mSv/MBq. CONCLUSION: Based on the distribution and dose estimates, the estimated radiation burden of [(18)F]FEDAA1106 is moderately higher than that of [(18)F]fluorodeoxyglucose (FDG). In clinical studies, the administered activity of this radioligand ought to be adjusted in line with regional regulations. This result would be helpful for further clinical TSPO imaging studies.
PURPOSE: [(18)F]FEDAA1106 is a recently developed positron emission tomography (PET) radioligand for in vivo quantification of the 18 kDa translocator protein [TSPO or, as earlier called, the peripheral benzodiazepine receptor (PBR)]. TSPO imaging is expected to be useful for the clinical evaluation of neuroinflammatory diseases. The aim of this study was to provide dosimetry estimates for [(18)F]FEDAA1106 based on human whole-body PET measurements. METHODS: PET scans were performed for a total of 6.6 h after the injection of 183.8 ± 9.1 MBq of [(18)F]FEDAA1106 in six healthy subjects. Regions of interest were drawn on coronal images. Estimates of the absorbed doses of radiation were calculated using the OLINDA software. RESULTS: Peak uptake was largest in lungs, followed by liver, small intestine, kidney, spleen and other organs. Peak values of the percent injected dose (%ID) at a time after radioligand injection were calculated for the lungs (27.1%ID at 0.2 h), liver (21.1%ID at 0.6 h), small intestine (10.4%ID at 6.3 h), kidney (4.9%ID at 1.8 h) and spleen (4.6%ID at 0.6 h). The largest absorbed dose was found in the spleen (0.12 mSv/MBq), followed by kidneys (0.094 mSv/MBq). The calculated mean effective dose was 0.036 mSv/MBq. CONCLUSION: Based on the distribution and dose estimates, the estimated radiation burden of [(18)F]FEDAA1106 is moderately higher than that of [(18)F]fluorodeoxyglucose (FDG). In clinical studies, the administered activity of this radioligand ought to be adjusted in line with regional regulations. This result would be helpful for further clinical TSPO imaging studies.
Authors: Anne Roivainen; Kjell Någren; Jussi Hirvonen; Vesa Oikonen; Pauliina Virsu; Tuula Tolvanen; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2008-12-03 Impact factor: 9.236
Authors: Vassilios Papadopoulos; Mario Baraldi; Tomás R Guilarte; Thomas B Knudsen; Jean-Jacques Lacapère; Peter Lindemann; Michael D Norenberg; David Nutt; Abraham Weizman; Ming-Rong Zhang; Moshe Gavish Journal: Trends Pharmacol Sci Date: 2006-07-05 Impact factor: 14.819
Authors: Jussi Hirvonen; Anne Roivainen; Jere Virta; Semi Helin; Kjell Någren; Juha O Rinne Journal: Eur J Nucl Med Mol Imaging Date: 2009-10-28 Impact factor: 9.236
Authors: Romina Mizrahi; Pablo M Rusjan; Irina Vitcu; Alvina Ng; Alan A Wilson; Sylvain Houle; Peter M Bloomfield Journal: Mol Imaging Biol Date: 2013-06 Impact factor: 3.488
Authors: Kornelis S M van der Geest; Maria Sandovici; Pieter H Nienhuis; Riemer H J A Slart; Peter Heeringa; Elisabeth Brouwer; William F Jiemy Journal: Front Med (Lausanne) Date: 2022-06-06
Authors: Neydher Berroterán-Infante; Theresa Balber; Petra Fürlinger; Michael Bergmann; Rupert Lanzenberger; Marcus Hacker; Markus Mitterhauser; Wolfgang Wadsak Journal: ACS Med Chem Lett Date: 2018-02-21 Impact factor: 4.345
Authors: Mathias Kranz; Bernhard Sattler; Solveig Tiepolt; Stephan Wilke; Winnie Deuther-Conrad; Cornelius K Donat; Steffen Fischer; Marianne Patt; Andreas Schildan; Jörg Patt; René Smits; Alexander Hoepping; Jörg Steinbach; Osama Sabri; Peter Brust Journal: EJNMMI Phys Date: 2016-10-21
Authors: Akihiro Takano; Fredrik Piehl; Jan Hillert; Andrea Varrone; Sangram Nag; Balázs Gulyás; Per Stenkrona; Victor L Villemagne; Christopher C Rowe; Richard Macdonell; Nabil Al Tawil; Thomas Kucinski; Torsten Zimmermann; Marcus Schultze-Mosgau; Andrea Thiele; Anja Hoffmann; Christer Halldin Journal: EJNMMI Res Date: 2013-04-24 Impact factor: 3.138